Dupilumab in pediatric dermatology.

Adolescent Antibodies, Monoclonal, Humanized / therapeutic use Child Dermatitis, Atopic / drug therapy Dermatology Humans Severity of Illness Index Treatment Outcome
Dupilumab children dermatology

Journal

The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 1 7 2020
medline: 8 4 2022
entrez: 1 7 2020
Statut: ppublish

Résumé

Dupilumab is a monoclonal antibody that targets the interleukin (IL)-4 receptor alpha subunit of the IL-4 and IL-13 receptor. This novel agent has received a license for the treatment of moderate-to-severe atopic dermatitis in patients aged ≥12 years. However, data on the dupilumab use in the pediatric population are still extremely limited. This report aims to summarize the existing data on the on- and off-label use of dupilumab for dermatologic conditions in children and adolescents. The current study is an overview of all the reported evidence on dupilumab for dermatologic conditions in the pediatric population. MEDLINE (PubMed), clinicaltrial.gov databases and SCOPUS were thoroughly scanned for related articles. A small number of clinical trials, case series and case reports, that indicate a satisfactory therapeutic outcome for dupilumab in pediatric patients for certain dermatologic conditions, is present in the literature. More long-term studies in larger patient groups are necessary so as to be able to draw definite conclusions concerning the efficacy and safety of dupilumab in pediatric patients with skin diseases.

Sections du résumé

BACKGROUND BACKGROUND
Dupilumab is a monoclonal antibody that targets the interleukin (IL)-4 receptor alpha subunit of the IL-4 and IL-13 receptor. This novel agent has received a license for the treatment of moderate-to-severe atopic dermatitis in patients aged ≥12 years. However, data on the dupilumab use in the pediatric population are still extremely limited. This report aims to summarize the existing data on the on- and off-label use of dupilumab for dermatologic conditions in children and adolescents.
MATERIALS AND METHODS METHODS
The current study is an overview of all the reported evidence on dupilumab for dermatologic conditions in the pediatric population. MEDLINE (PubMed), clinicaltrial.gov databases and SCOPUS were thoroughly scanned for related articles.
RESULTS RESULTS
A small number of clinical trials, case series and case reports, that indicate a satisfactory therapeutic outcome for dupilumab in pediatric patients for certain dermatologic conditions, is present in the literature.
CONCLUSION CONCLUSIONS
More long-term studies in larger patient groups are necessary so as to be able to draw definite conclusions concerning the efficacy and safety of dupilumab in pediatric patients with skin diseases.

Identifiants

DOI: 10.1080/09546634.2020.1789049 PMID: 32602761
pubmed: 32602761
doi: 10.1080/09546634.2020.1789049
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
dupilumab 420K487FSG

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

682-684

Auteurs

Kerasia-Maria Plachouri (KM)

Dermatology Department, University of Patras, Greece, University General Hospital of Patras, Rio, Greece.

Sophia Georgiou (S)

Dermatology Department, University of Patras, Greece, University General Hospital of Patras, Rio, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Dupilumab in pediatric dermatology.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Dupilumab in pediatric dermatology.
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Dupilumab in pediatric dermatology.
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Eczéma atopique › Dupilumab in pediatric dermatology.
questionsmedicales.fr › Professions de santé › Médecine › Dermatologie › Dupilumab in pediatric dermatology.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Dupilumab in pediatric dermatology.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Dupilumab in pediatric dermatology.
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Dupilumab in pediatric dermatology.